SRT3025 HCl
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 555374

CAS#: 2070015-26-6 (HCl)

Description: SRT3025 is a potent and selective Sirt1 activator. SRT3025 Inhibits RANKL-Induced Osteoclastogenesis in Bone Marrow-Derived Macrophages and Down-Regulate Sirt3 in Sirt1 Null Cells. SRT3025 down-regulates sclerostin and rescues ovariectomy-induced bone loss and biomechanical deterioration in female mice. SRT3025 provides atheroprotection in Apoe-/- mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression.


Price and Availability

Size
Price

50mg
USD 550
500mg
USD 2150
5g
USD 8950
Size
Price

100mg
USD 950
1g
USD 3450
Size
Price

200mg
USD 1450
2g
USD 5950

SRT3025 HCl, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 555374
Name: SRT3025 HCl
CAS#: 2070015-26-6 (HCl)
Chemical Formula: C31H32ClN5O2S2
Exact Mass:
Molecular Weight: 606.2
Elemental Analysis: C, 61.42; H, 5.32; Cl, 5.85; N, 11.55; O, 5.28; S, 10.58


Related CAS #: 1231952-55-8 (free base)   2070015-26-6 (HCl)    

Synonym: SRT3025 HCl; SRT3025 hydrochloride; SRT3025; SRT-3025; SRT 3025;

IUPAC/Chemical Name: 5-(3-methoxypropyl)-2-phenyl-N-(2-(6-(pyrrolidin-1-ylmethyl)thiazolo[5,4-b]pyridin-2-yl)phenyl)thiazole-4-carboxamide hydrochloride

InChi Key: LGRBDTOIPNDWMN-UHFFFAOYSA-N

InChi Code: InChI=1S/C31H31N5O2S2.ClH/c1-38-17-9-14-26-27(35-29(39-26)22-10-3-2-4-11-22)28(37)33-24-13-6-5-12-23(24)30-34-25-18-21(19-32-31(25)40-30)20-36-15-7-8-16-36;/h2-6,10-13,18-19H,7-9,14-17,20H2,1H3,(H,33,37);1H

SMILES Code: C1C=C(C2SC(CCCOC)=C(C(NC3C=CC=CC=3C3=NC4=C(N=CC(=C4)CN4CCCC4)S3)=O)N=2)C=CC=1.Cl


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
2934.99.03.00


References

1: Zhang Y, Thai K, Jin T, Woo M, Gilbert RE. SIRT1 activation attenuates α cell hyperplasia, hyperglucagonaemia and hyperglycaemia in STZ-diabetic mice. Sci Rep. 2018 Sep 18;8(1):13972. doi: 10.1038/s41598-018-32351-z. PubMed PMID: 30228292; PubMed Central PMCID: PMC6143559.

2: Zhang Y, Connelly KA, Thai K, Wu X, Kapus A, Kepecs D, Gilbert RE. Sirtuin 1 Activation Reduces Transforming Growth Factor-β1-Induced Fibrogenesis and Affords Organ Protection in a Model of Progressive, Experimental Kidney and Associated Cardiac Disease. Am J Pathol. 2017 Jan;187(1):80-90. doi: 10.1016/j.ajpath.2016.09.016. PubMed PMID: 27993241.

3: Opal SM, Ellis JL, Suri V, Freudenberg JM, Vlasuk GP, Li Y, Chahin AB, Palardy JE, Parejo N, Yamamoto M, Chahin A, Kessimian N. PHARMACOLOGICAL SIRT1 ACTIVATION IMPROVES MORTALITY AND MARKEDLY ALTERS TRANSCRIPTIONAL PROFILES THAT ACCOMPANY EXPERIMENTAL SEPSIS. Shock. 2016 Apr;45(4):411-8. doi: 10.1097/SHK.0000000000000528. PubMed PMID: 26974318.

4: El-Haj M, Gurt I, Cohen-Kfir E, Dixit V, Artsi H, Kandel L, Yakubovsky O, Safran O, Dresner-Pollak R. Reduced Sirtuin1 expression at the femoral neck in women who sustained an osteoporotic hip fracture. Osteoporos Int. 2016 Jul;27(7):2373-2378. doi: 10.1007/s00198-016-3536-4. Epub 2016 Feb 22. PubMed PMID: 26902093.

5: Chini CC, Espindola-Netto JM, Mondal G, Guerrico AM, Nin V, Escande C, Sola-Penna M, Zhang JS, Billadeau DD, Chini EN. SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway. Clin Cancer Res. 2016 May 15;22(10):2496-507. doi: 10.1158/1078-0432.CCR-15-1760. Epub 2015 Dec 11. PubMed PMID: 26655844; PubMed Central PMCID: PMC4867252.

6: Kim HN, Han L, Iyer S, de Cabo R, Zhao H, O'Brien CA, Manolagas SC, Almeida M. Sirtuin1 Suppresses Osteoclastogenesis by Deacetylating FoxOs. Mol Endocrinol. 2015 Oct;29(10):1498-509. doi: 10.1210/me.2015-1133. Epub 2015 Aug 19. PubMed PMID: 26287518; PubMed Central PMCID: PMC4588729.

7: Gurt I, Artsi H, Cohen-Kfir E, Hamdani G, Ben-Shalom G, Feinstein B, El-Haj M, Dresner-Pollak R. The Sirt1 Activators SRT2183 and SRT3025 Inhibit RANKL-Induced Osteoclastogenesis in Bone Marrow-Derived Macrophages and Down-Regulate Sirt3 in Sirt1 Null Cells. PLoS One. 2015 Jul 30;10(7):e0134391. doi: 10.1371/journal.pone.0134391. eCollection 2015. PubMed PMID: 26226624; PubMed Central PMCID: PMC4520518.

8: Zhang QS, Deater M, Schubert K, Marquez-Loza L, Pelz C, Sinclair DA, Grompe M. The Sirt1 activator SRT3025 expands hematopoietic stem and progenitor cells and improves hematopoiesis in Fanconi anemia mice. Stem Cell Res. 2015 Jul;15(1):130-40. doi: 10.1016/j.scr.2015.05.007. Epub 2015 May 22. PubMed PMID: 26046330; PubMed Central PMCID: PMC4516677.

9: Gilbert RE, Thai K, Advani SL, Cummins CL, Kepecs DM, Schroer SA, Woo M, Zhang Y. SIRT1 activation ameliorates hyperglycaemia by inducing a torpor-like state in an obese mouse model of type 2 diabetes. Diabetologia. 2015 Apr;58(4):819-27. doi: 10.1007/s00125-014-3485-4. Epub 2015 Jan 7. PubMed PMID: 25563725.

10: Li Y, Shen G, Yu C, Li G, Shen J, Gong J, Xu Y. Angiotensin II induces mitochondrial oxidative stress and mtDNA damage in osteoblasts by inhibiting SIRT1–FoxO3a–MnSOD pathway. Biochem Biophys Res Commun. 2014 Dec 5;455(1-2):113-8. PubMed PMID: 25450701.

11: Artsi H, Cohen-Kfir E, Gurt I, Shahar R, Bajayo A, Kalish N, Bellido TM, Gabet Y, Dresner-Pollak R. The Sirtuin1 activator SRT3025 down-regulates sclerostin and rescues ovariectomy-induced bone loss and biomechanical deterioration in female mice. Endocrinology. 2014 Sep;155(9):3508-15. doi: 10.1210/en.2014-1334. Epub 2014 Jun 20. PubMed PMID: 24949665.

12: Miranda MX, van Tits LJ, Lohmann C, Arsiwala T, Winnik S, Tailleux A, Stein S, Gomes AP, Suri V, Ellis JL, Lutz TA, Hottiger MO, Sinclair DA, Auwerx J, Schoonjans K, Staels B, Lüscher TF, Matter CM. The Sirt1 activator SRT3025 provides atheroprotection in Apoe-/- mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression. Eur Heart J. 2015 Jan 1;36(1):51-9. doi: 10.1093/eurheartj/ehu095. Epub 2014 Mar 6. PubMed PMID: 24603306; PubMed Central PMCID: PMC4286317.